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Development of therapeutic cancer vaccines has largely been based on rodent models and the majority 
failed to establish therapeutic responses in clinical trials. Since the porcine immunome is closely 
related to the human counterpart, using pigs as a large animal model for human cancer vaccine 
development has great potential. We administered peptides derived from porcine IDO, a cancer antigen 
important in human disease, formulated in Th1-inducing adjuvants to outbred pigs. By in silico 
prediction 136 candidate IDO-derived peptides were identified and peptide-SLA class I complex 
stability measurements revealed 89 stable (t½ ≥ 0.5 hour) complexes with expressed SLA alleles. We 
showed that using our immunization strategy it was possible to break the peripheral tolerance and 
induce a cell-mediated response to an endogenous antigen. Mounting a proper Th1 response is highly 
dependent on peptide dose; we therefore designed a dose titration study with 15 Göttingen minipigs 
receiving intraperitoneal injections of either 1 µg, 10 µg or 100 µg of 30-31mer peptides covering the 
majority of IDO-derived potential cytotoxic T lymphocyte (CTL) epitopes. Peptides were formulated in 
CAF09, an adjuvant comprised of cationic DDA liposomes decorated with poly (I:C) and MMG as 
immune modulators. Interestingly, the 1 µg group was the only one showing responses to all 
immunization peptides following seven injections as determined by IFN-γ ELISpot. These data show 
that a reduction in dose can result in a highly specific Th1-biased response. To test the CTL 
functionality we designed an in vivo cytotoxicity assay, where purified PBMCs fluorescently labelled 
and pulsed with IDO-derived target peptides were administered intravenously back into each donor and 
killing capacity was measured by flow cytometry. In some animals we observed indications of in vivo 
specific killing of peptide-pulsed target cells as compared to control cells also fluorescently labelled 
with a different dye.  
 
